OverviewSuggest Edit

Ypsomed develops, manufactures and sells injection and infusion systems for pharmaceutical and biotechnology companies. The Company operates through Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others segments. The Ypsomed Delivery Systems segment offers various injection systems, such as pen injectors, auto injectors and dual-chamber pens, as well as insulin pens, other diabetes pens, pens for growth hormones and other pens. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories and other day-to-day items for diabetics. The Others segment offers precision turned parts.

TypePublic
Founded2003
HQBurgdorf, CH
Websiteypsomed.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Jul 2021)1,737(-3%)
Share Price (Sept 2021)CHF146.8
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Ypsomed

Simon Michel

Simon Michel

Chief Executive Officer
Willy Michel

Willy Michel

Chairman
Niklaus Ramseier

Niklaus Ramseier

Chief Financial Officer (CFO)
Frank Mengis

Frank Mengis

Chief Operating Officer (COO)
Hans Ulrich Lehmann

Hans Ulrich Lehmann

Senior Vice President Technology
Michael Zaugg

Michael Zaugg

Senior Vice President Human Resources
Show more

Ypsomed Office Locations

Ypsomed has offices in Burgdorf, Solothurn, Mona Vale, Wien and in 15 other locations
Burgdorf, CH (HQ)
Brunnmattstrasse 6
Burgdorf, CH
Buchmattstrasse 100
Solothurn, CH
Weissensteinstrasse 26
Mona Vale, AU
602/20 Bungan St
Wien, AT
Am Europl. 2
Anderlecht, BE
Researchdreef 12
Show all (21)

Ypsomed Financials and Metrics

Ypsomed Revenue

Market capitalization (20-Sept-2021)

1.9b

Closing stock price (20-Sept-2021)

146.8
Ypsomed's current market capitalization is CHF1.9 b.
Show all financial metrics

Ypsomed Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Ypsomed Online and Social Media Presence

Embed Graph

Ypsomed News and Updates

Insights on the Injectable Packaging and Component Global Market to 2025 - Featuring West Pharmaceuticals, Gerresheimer, Ypsomed and Datwyler Holding Among Others

Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "Global Injectable Packaging and Component Market: Size, Trends & Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Patient Controlled Injectors Market to sale $ 7,505.70 million by 2027 | Ypsomed AG, Enable Injections, scPharmaceuticals, Gerresheimer AG

The patient controlled market was valued at US$ 2,969.47 million in 2019 and is projected to reach US$ 7,505.70 million by 2027; it is expected to grow at a CAGR of 12.4% from 2020 to 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions. Under the...

Diabetes Insulin Delivery Pens Market Major Key Players Are Novo Nordisk, Novo Nordisk, Sanofi, Ypsomed and Biocon Ltd.

New Report on Global Diabetes Insulin Delivery Pens Market 2019 Edition Posted via Industry Today. Follow us on Twitter @IndustryToday

Insulin Pumps: Worldwide Market Projections to 2024 Featuring Medtronics, Roche Diagnostics, Ypsomed, Animus Corp, and More

DUBLIN, July 1, 2019 /PRNewswire/ -- The "Insulin Pumps Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering. The global insulin pumps market was worth US$ 3.9 Billion in 2018. Looking forward,...

Explosive growth on Global Flash glucose monitoring system Market 2019 | Senseonics, Animas, Dexcom, Glysens, Medtronic, Omnipod, Roche, Ypsomed

Flash glucose monitoring is the latest method of glucose testing, which appears to be a hybrid between the meter and the CGM. In Flash Glucose Monitoring, patients inserted the sensor into a separate touchscreen reader device. Posted via Industry Today. Follow us on Twitter @IndustryToday

Ypsomed Frequently Asked Questions

  • When was Ypsomed founded?

    Ypsomed was founded in 2003.

  • Who are Ypsomed key executives?

    Ypsomed's key executives are Simon Michel, Willy Michel and Niklaus Ramseier.

  • How many employees does Ypsomed have?

    Ypsomed has 1,737 employees.

  • Who are Ypsomed competitors?

    Competitors of Ypsomed include GlucoRx, Metavention and GI Windows.

  • Where is Ypsomed headquarters?

    Ypsomed headquarters is located at Brunnmattstrasse 6, Burgdorf.

  • Where are Ypsomed offices?

    Ypsomed has offices in Burgdorf, Solothurn, Mona Vale, Wien and in 15 other locations.

  • How many offices does Ypsomed have?

    Ypsomed has 21 offices.